BNT212 / BioNTech - LARVOL DELTA

A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=375 | Recruiting | Sponsor: BioNTech SE | Trial completion date: Mar 2028 ➔ Aug 2028

First-in-human • Monotherapy • Trial completion date • Oncology • Solid Tumor

A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=375 | Recruiting | Sponsor: BioNTech SE | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Monotherapy • Solid Tumor

A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=375 | Not yet recruiting | Sponsor: BioNTech SE

Monotherapy • New P1/2 trial • Solid Tumor